Arcus Biosciences, Inc. (RCUS): Total Assets
$1.14B
As of 2025-12-31
$924.00M
As of 2026-06-30
-5.4%
3-year compound annual growth
+8.1%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.14B | -1.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $1.15B | +5.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $1.09B | -18.6% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $1.34B | -15.5% | 2024-02-21, Balance as of period end |
| 2021-12-31 | $1.59B | +106.1% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $772.29M | +280.2% | 2022-02-23, Balance as of period end |
| 2019-12-31 | $203.11M | -26.1% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $274.93M | +44.3% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $190.49M | n/a | 2019-03-05, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $1.14B | -1.0% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $726.16M | -11.8% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $364.39M | -24.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $717.90M | -34.2% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $216.30M | +1.4% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.56B | +65.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $817.15M | +193.0% |
Compare RCUS, KROS, SDGR, AKBA side by side · Screen every company in Pharmaceutical Preparations ↗